Menu

Press Releases

Sanofi-aventis U.S. Announces New Addition to Diabetes Medical Leadership Team

Bridgewater, N.J. – January 12, 2011 – Sanofi-aventis U.S. announced today the addition of new medical leadership to the Diabetes Division.  Robert Cuddihy, M.D., has been appointed Vice President, Medical Diabetes Head in the U.S, and will be responsible for developing and executing the U.S. medical affairs strategy for the Diabetes Division, including pharmaceuticals, devices and other technologies.  Dr. Cuddihy joins Michelle Baron, M.D., Vice President, Medical Diabetes U.S., who will continue her role directing multiple projects and seeking, evaluating and capitalizing on business development opportunities for the Diabetes Division.  

The sanofi-aventis Diabetes Division integrates all relevant R&D, medical, commercial and device development activities to maximize the company’s core strengths in the field and deliver innovative and integrated solutions for people living with diabetes.

Dr. Cuddihy will be based in Bridgewater, NJ, and he will also work closely with the sanofi-aventis global Diabetes Division based in Frankfurt, Germany.

"We are very pleased to welcome Dr. Cuddihy to the sanofi-aventis diabetes team,” said Paul Chew, Senior Vice President, U.S. Chief Science Officer and Chief Medical Officer, sanofi-aventis U.S. “His more than 15 years of experience working in the diabetes field as well as his organizational and program management expertise will be invaluable in the continued development of the Diabetes Division."

Prior to joining sanofi-aventis U.S., Dr. Cuddihy served as the Medical Director for several organizations, including the International Diabetes Center- Park-Nicollet, a World Health Organization Collaborating Center for Diabetes Education, Translation and Computer Technology. He was also a staff physician at Park Nicollet Clinics, Methodist Hospital, and the University of Minnesota Physicians.  In addition, he was a member of the Park Nicollet Institutional Review Board and Chair of the Park Nicollet Research Institute Research Committee. His past associations have included the Mayo Clinic and Medical School, Massachusetts General Hospital and Harvard Medical School, and Newton-Wellesley Hospital.

Dr. Cuddihy received his medical degree at the University of Massachusetts Medical School in Worcester and conducted his postdoctoral training at the Maine Medical Center and the Mayo Clinic.

About the sanofi-aventis Diabetes Division

Sanofi-aventis strives to deliver innovative and integrated patient-focused solutions for people living with diabetes. The Company currently has insulin products that are also available in injection pens for people with type 1 or type 2 diabetes, as well as an oral, once-daily sulfonylurea treatment for type 2 diabetes.  In order to provide comprehensive care in diabetes management, sanofi-aventis is also introducing devices such as innovative blood glucose monitoring systems.  Investigational compounds in the pipeline include the potential first regenerative treatment for diabetes as well as a once-daily injectable GLP-1 agonist to be used alone, in combination with basal insulins, and/or in combination with oral antidiabetic agents.

About sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit www.sanofi-aventis.us or www.sanofi-aventis.com.

#  #  #

Media Contact:

Susan Brooks
Susan.Brooks@sanofi-aventis.com
908-981-6566